Klonopin Alternatives Compared
| Klonopin (clonazepam) | Topiramate | Keppra (levetiracetam) |
|
|---|
| Klonopin (clonazepam) | Topiramate | Keppra (levetiracetam) |
|
|||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Klonopin may be used in the treatment of panic disorder and certain types of seizure disorder. Sedation is the most common side effect and it can cause both physical and psychological dependence... View more |
Prescription only
Topiramate may be prescribed either alone or in combination with other medications for the treatment of certain types of epilepsy, or it may be given for the prevention of migraines. Drowsiness is a... View more |
Prescription only
Keppra is an anticonvulsant that is used in conjunction with other medications for the treatment of certain types of seizures. It may cause drowsiness but it is less likely than some other... View more |
Related suggestions |
|||||||||||||||||||||||
| More about Klonopin (clonazepam) | More about Topiramate | More about Keppra (levetiracetam) | ||||||||||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||||||||||
|
Klonopin has an average rating of 8.5 out of 10 from a total of 758 ratings on Drugs.com. 83% of reviewers reported a positive effect, while 10% reported a negative effect. |
Topiramate has an average rating of 6.3 out of 10 from a total of 1337 ratings on Drugs.com. 50% of reviewers reported a positive effect, while 28% reported a negative effect. |
Keppra has an average rating of 5.7 out of 10 from a total of 309 ratings on Drugs.com. 43% of reviewers reported a positive effect, while 34% reported a negative effect. |
||||||||||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||||||||||
View all Klonopin side effects |
View all Topiramate side effects |
View all Keppra side effects |
||||||||||||||||||||||||
| Drug Class | ||||||||||||||||||||||||||
| Generic Availability | ||||||||||||||||||||||||||
|
Lower cost generic |
||||||||||||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all Klonopin prices |
View all Topiramate prices |
View all Keppra prices |
||||||||||||||||||||||||
| Dosage Forms | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
| Brand Names | ||||||||||||||||||||||||||
|
N/A |
Eprontia, Qudexy XR, Topamax, Trokendi XR | Other levetiracetam brands include: Elepsia XR, Keppra XR, Roweepra, Roweepra XR, Spritam | ||||||||||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||||||||||
|
40 hours |
56 hours |
8 hours |
||||||||||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||||||||||
|
Some potential for abuse
Has a low potential for abuse relative to those in schedule 3. It has a currently accepted medical use in treatment in the United States. Abuse may lead to limited physical dependence or psychological dependence relative to those in schedule 3. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
| Pregnancy Category | ||||||||||||||||||||||||||
|
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
||||||||||||||||||||||||
| Drug Interactions | ||||||||||||||||||||||||||
|
A total of 533 drugs are known to interact with Klonopin:
|
A total of 291 drugs are known to interact with Topiramate:
|
A total of 239 drugs are known to interact with Keppra:
|
||||||||||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
| Disease Interactions | ||||||||||||||||||||||||||
| First Approval Date | ||||||||||||||||||||||||||
|
June 04, 1975 |
December 24, 1996 |
November 30, 1999 |
||||||||||||||||||||||||
| WADA Class View classifications | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| More Information | ||||||||||||||||||||||||||
| Patient Resources | ||||||||||||||||||||||||||
| Professional Resources | ||||||||||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||||||||||
|
||||||||||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.